XRCC3 and colonic neoplasm: These findings indicate that rs744591 might through dysregulating miR-3196 and its targets, such as CDA, DHFR, FPGS, SMUG1, UMPS, and/or XRCC3 (Table 3), leads to individual response of capecitabine-based chemotherapy in advanced colon cancer patients.